

# PRIOR AUTHORIZATION CRITERIA

**BRAND NAME**  
(generic)

**STROMEKTOL**  
(ivermectin)

**Status: CVS Caremark® Criteria**

**Type: Initial Prior Authorization with Quantity Limit**

## POLICY

### FDA-APPROVED INDICATIONS

Stromectol is indicated for the treatment of the following infections:

#### Strongyloidiasis of the intestinal tract

Stromectol is indicated for the treatment of intestinal (i.e., non-disseminated) strongyloidiasis due to the nematode parasite *Strongyloides stercoralis*.

#### Onchocerciasis

Stromectol is indicated for the treatment of onchocerciasis due to the nematode parasite *Onchocerca volvulus*.

Stromectol has no activity against adult *Onchocerca volvulus* parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.

## COVERAGE CRITERIA

### **Coronavirus Disease 2019 (COVID-19)**

Authorization may be granted when the requested drug is NOT being prescribed for the prevention or treatment of coronavirus disease 2019 (COVID-19)

### QUANTITY LIMITS APPLY

9 tablets per 75 days\*

\*The duration of 75 days is used for a 90-day fill period.

### DURATION OF APPROVAL (DOA)

- 4909-C: DOA: 3 months

## REFERENCES

1. Stromectol [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; May 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed December 4, 2023.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 12/04/2023).
4. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed December 4, 2023.
5. Therapeutics and COVID-19: living guideline, 13 January 2023. Geneva: World Health Organization; 2023 (WHO/2019-nCoV/therapeutics/2023.1). Accessed December 4, 2023.

Ivermectin (Oral) PA with Limit COVID19 Policy 4909-C UDR 01-2024

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

6. Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015–2018. National Center for Health Statistics. Vital Health Stat 3(46). January 2021.

Ivermectin (Oral) PA with Limit COVID19 Policy 4909-C UDR 01-2024

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423